Metabolic & weight · Peptide
Semaglutide
Also known as Ozempic, Wegovy, Rybelsus
A long-acting copy of the gut hormone GLP-1 that calms appetite and steadies blood sugar.
Status as of 2026-07 · reclassification ≠ FDA approval · educational only, not medical advice.
The signal it sends
Activates GLP-1 receptors in pancreas (insulin), stomach (slower emptying) and brain (less hunger).
Benefits & effects studied
- ~15% average weight loss
- Strong blood-sugar control
- Lower cardiovascular events (SELECT trial)
- Under study for brain & liver aging
Research state
Extensive Phase III evidence; approved for diabetes & obesity; cardiovascular benefit proven.
Dosing & pharmacokinetics
Weekly subcutaneous injection (or daily oral Rybelsus), titrated over weeks. Half-life: ~7 days (once-weekly dosing).
Dosing information is educational only. Semaglutide decisions belong with a licensed clinician — Jevity does not recommend or supply dosing.
History & discovery
First described 2012 by Novo Nordisk (Lotte Bjerre Knudsen; chemists Jesper Lau, Thomas Kruse, Paw Bloch) Origin: Developed at Novo Nordisk as a follow-up to liraglutide, with chemists testing thousands of linker and fatty-acid combinations to create an ultrastable, once-weekly GLP-1 receptor agonist; phase II trials began in 2008 and it was approved as Ozempic in 2017..
Molecular structure
A 31-amino-acid peptide based on human GLP-1, with a DPP-4-resistant mutation and a fatty-acid chain attached via a linker to lysine 26 for albumin binding.
Frequently asked questions
Is Semaglutide FDA-approved?
FDA-approved (Ozempic®, Wegovy®) On Jevity's evidence scale, Semaglutide is graded "FDA-approved". Reclassification for compounding is not the same as FDA approval.
What is Semaglutide used for?
A long-acting copy of the gut hormone GLP-1 that calms appetite and steadies blood sugar. Activates GLP-1 receptors in pancreas (insulin), stomach (slower emptying) and brain (less hunger). Studied effects include: ~15% average weight loss; Strong blood-sugar control; Lower cardiovascular events (SELECT trial); Under study for brain & liver aging. This is educational information, not a recommendation to use it.
Is Semaglutide legal in the UAE?
UAE / DHA status: Prescription medicine — DHA-licensed provider
Is Semaglutide banned in sport?
WADA status: Not prohibited
What is Semaglutide's Jevity Score?
Semaglutide has a Jevity Score of 100/100 — a proprietary composite of evidence strength (10/10), regulatory clarity (10/10) and supply verifiability (10/10). It reflects how established and legitimate the compound is, not a recommendation.
Related metabolic & weight peptides
Educational information only — not medical advice, a diagnosis, or a recommendation to use any substance or therapy. Regulatory status changes; verify current rules and any personal decision with a licensed clinician. Jevity is operated by Upcapital Global FZCO, Dubai, UAE.